Online inquiry

IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12508MR)

This product GTTS-WQ12508MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MUC5AC gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001304359.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4586
UniProt ID P98088
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12508MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10360MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ11492MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ15302MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ11333MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ11301MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ10524MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ12401MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ10213MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW